Protalix BioTherapeutics (PLX) Competitors

Protalix BioTherapeutics (NYSE:PLX) and Atai Life Sciences (NASDAQ:ATAI) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, valuation, institutional ownership, media sentiment, dividends, earnings, risk and community ranking.

Which has preferable earnings & valuation, PLX or ATAI?

Protalix BioTherapeutics has higher revenue and earnings than Atai Life Sciences. Atai Life Sciences is trading at a lower price-to-earnings ratio than Protalix BioTherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protalix BioTherapeutics	$59.76M	2.05	$8.31M	$0.04	38.50
Atai Life Sciences	$1.86M	234.43	-$40.22M	-$0.91	-2.40

Does the MarketBeat Community believe in PLX or ATAI?

Atai Life Sciences received 323 more outperform votes than Protalix BioTherapeutics when rated by MarketBeat users. However, 81.25% of users gave Protalix BioTherapeutics an outperform vote while only 66.40% of users gave Atai Life Sciences an outperform vote.

Company	Underperform	Outperform
Protalix BioTherapeutics	Outperform Votes 13 81.25%	Underperform Votes 3 18.75%
Atai Life Sciences	Outperform Votes 336 66.40%	Underperform Votes 170 33.60%

Do insiders & institutionals have more ownership in PLX or ATAI?

16.5% of Protalix BioTherapeutics shares are held by institutional investors. Comparatively, 28.4% of Atai Life Sciences shares are held by institutional investors. 6.5% of Protalix BioTherapeutics shares are held by insiders. Comparatively, 26.8% of Atai Life Sciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Do analysts recommend PLX or ATAI?

Protalix BioTherapeutics currently has a consensus price target of $15.00, indicating a potential upside of 874.03%. Atai Life Sciences has a consensus price target of $8.67, indicating a potential upside of 297.55%. Given Protalix BioTherapeutics' higher possible upside, analysts clearly believe Protalix BioTherapeutics is more favorable than Atai Life Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protalix BioTherapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Atai Life Sciences	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	3.33

Which has more volatility & risk, PLX or ATAI?

Protalix BioTherapeutics has a beta of -0.21, indicating that its stock price is 121% less volatile than the S&P 500. Comparatively, Atai Life Sciences has a beta of 1.48, indicating that its stock price is 48% more volatile than the S&P 500.

Does the media refer more to PLX or ATAI?

In the previous week, Atai Life Sciences had 1 more articles in the media than Protalix BioTherapeutics. MarketBeat recorded 1 mentions for Atai Life Sciences and 0 mentions for Protalix BioTherapeutics. Atai Life Sciences' average media sentiment score of 1.29 beat Protalix BioTherapeutics' score of 0.00 indicating that Atai Life Sciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Protalix BioTherapeutics	Neutral
Atai Life Sciences	Positive

Is PLX or ATAI more profitable?

Atai Life Sciences has a net margin of 0.00% compared to Protalix BioTherapeutics' net margin of -21.03%. Protalix BioTherapeutics' return on equity of -30.89% beat Atai Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Protalix BioTherapeutics	-21.03%	-30.89%	-11.74%
Atai Life Sciences	N/A	-65.75%	-52.71%

Summary

Atai Life Sciences beats Protalix BioTherapeutics on 12 of the 19 factors compared between the two stocks.